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Background: There is a high prevalence of smoking and high burden of tobacco-related diseases among
low-income populations. Effective, evidenced-based smoking cessation treatments are available, but low-income
smokers are less likely than higher-income smokers to use these treatments, especially the most comprehensive
forms that include a combination of pharmacotherapy and intensive behavioral counseling.
Methods/Design: The primary objectives of this randomized controlled trial are to compare the effects of a
proactive tobacco treatment intervention compared to usual care on population-level smoking abstinence rates
and tobacco treatment utilization rates among a diverse population of low-income smokers, and to determine
the cost-effectiveness of proactive tobacco treatment intervention. The proactive care intervention systematically
offers low-income smokers free and easy access to evidence-based treatments and has two primary components:
(1) proactive outreach to current smokers in the form of mailed invitation materials and telephone calls containing
targeted health messages, and (2) facilitated access to free, comprehensive, evidence-based tobacco cessation
treatments in the form of NRT and intensive, telephone-based behavioral counseling. The study aims to include
a population-based sample (N = 2500) of adult smokers enrolled in the Minnesota Health Care Programs (MHCP),
a state-funded health insurance plan for low-income persons. Baseline data is obtained from MHCP administrative
databases and a participant survey that is conducted prior to randomization. Outcome data is collected from a
follow-up survey conducted 12 months after randomization and MHCP administrative data. The primary outcome
is six-month prolonged smoking abstinence at one year and is assessed at the population level. All randomized
individuals are asked to complete the follow-up survey, regardless of whether they participated in tobacco
treatment. Data analysis of the primary aims will follow intent-to-treat methodology.
Discussion: There is a critical need to increase access to effective tobacco dependence treatments. This
randomized trial evaluates the effects of proactive outreach coupled with free NRT and telephone counseling
on the population impact of tobacco dependence treatment. If proven to be effective and cost-effective, national
dissemination of proactive treatment approaches would reduce tobacco-related morbidity, mortality, and health
care costs for low income Americans.
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Tobacco use rates are alarmingly high in low-income
populations. In the United States, 27.9% of adults living
below the federal poverty level smoke cigarettes com-
pared to 17% of adults at or above the poverty level [1].
About 34% of adult Medicaid enrollees currently smoke
cigarettes, and racial/ethnic minorities and women are
disproportionally represented in the Medicaid popula-
tion [2]. Smoking rates in the uninsured population are
similar to the Medicaid population and higher than
the general population (32% compared to 16% for ages
18–65) [2]. Smokers with lower incomes are also less
likely to use evidence-based smoking cessation treat-
ments such as pharmacotherapy and counseling than
smokers with higher incomes [3-8]. In an analysis of the
2000 National Health Interview Survey, among smokers
who were attempting to quit, only 15.5% of Medicaid
enrollees used a cessation aid compared to 25.4% of
individuals with private health insurance [6]. Conse-
quently, low income populations experience an excess
burden of tobacco-related morbidity and mortality. Add-
itionally, this group can least afford the cost of cigarettes
(an average of $2017 per year in the US) [9].
Over the past decade, coverage for tobacco depend-
ence treatments by federal-state Medicaid programs has
improved, but significant limitations remain. For ex-
ample, the number of state Medicaid programs provid-
ing some coverage for tobacco dependence treatment
increased from 25 in 1998 [10] to 47 in 2009 [11]. How-
ever, in 2009, only 18 state Medicaid programs covered
individual cessation counseling for all of their enrollees.
Most programs also require co-payments for tobacco de-
pendence treatments (over 70%) and many require prior
authorization. In addition, knowledge of Medicaid cover-
age for tobacco dependence treatments is low among
Medicaid enrolled smokers and their physicians. In a
2004 study of enrollees and physicians from two state
Medicaid programs with full coverage for nicotine re-
placement therapy (NRT), only 21% of enrollees and
46% of physicians were aware of this coverage [12]. In a
2003 study of tobacco cessation coverage awareness
among New York state Medicaid enrollees, only 7% of
those surveyed were aware that their state Medicaid pro-
gram covered NRT [13].
Both patient-level and provider-level factors contribute
to disparities in use of tobacco cessation treatment.
Current approaches typically depend on either a smoker’s
initiative to actively seek treatment or a clinical encounter
in which the provider has the time, willingness, and cap-
acity to deliver quality smoking cessation care [8,14]. Low
income smokers may be less likely to seek treatment
because of significant life stressors that reduce their
motivation to quit, lower levels of knowledge about the
benefits of pharmacotherapy as well as unaware that theirstate Medicaid program covers these treatments [15-17].
In addition, low income smokers experience unique, sig-
nificant barriers to health care access and are vulnerable
to health care providers’ assumptions about lack of inter-
est in quitting [18,19].
Effective strategies are needed to provide increased ac-
cess to evidence-based tobacco treatments, especially for
low-income populations. In this paper, we describe the
study design and methods of a prospective randomized
controlled trial testing a proactive tobacco intervention
that is hypothesized to have greater population impact
because it will 1) achieve wide reach and increase
utilization of treatment (proactive outreach with offer of
free NRT and easy access to telephone care) and 2) in-
crease the effectiveness of treatment (by efficient deliv-
ery of free NRT and intensive behavioral counseling).
This proactive tobacco treatment intervention integrates
population-based and individual approaches to address




We will examine the population impact of a proactive
care intervention in a population-based sample of adult
smokers enrolled in the Minnesota Health Care Pro-
grams (MHCP). MHCP is a state-funded health insur-
ance plan, administered by the Minnesota Department
of Human Services (DHS), for low income persons and
families comprising two major publicly subsidized health
care assistance programs: Medicaid and MinnesotaCare.
MinnesotaCare is for Minnesota residents that do
not have access to affordable health care coverage and
funded by a state tax on Minnesota hospitals and health
care providers, Medicaid and enrollee premiums. The
proactive tobacco intervention being tested has two pri-
mary components: 1) outreach to current smokers in the
form of tailored mailings and telephone calls, and 2) fa-
cilitated access to a free, comprehensive, evidence-based
treatment for tobacco dependence in the form of NRT
and intensive, telephone-based behavioral counseling.
This proactive approach is designed to overcome the
predominant barriers to smoking cessation treatment
(provider-based, access to care, and psychosocial) experi-
enced by low-income smokers. Further, to assess the
population impact of smoking cessation treatment, we
include all smokers, regardless of their interest in quit-
ting or participation in the offered treatment. This is in
contrast to studies designed to test the efficacy of an
intervention in smokers who have indicated strong inter-
est in quitting.
The study is a two group randomized controlled trial
(see Figure 1) and was approved by the Institutional
Review Boards at the University of Minnesota and the
Figure 1 Study design.
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population is stratified by age group (18–24, 25–34, and
35–64), by gender, and by healthcare program (Medicaid
and MinnesotaCare). Stratified program enrollee data is
obtained from MHCP administrative databases and a
baseline participant screening survey conducted prior
to randomization to assess current tobacco use as well
as additional baseline information. Survey recruitment
from the strata follows the proportions present in
the MHCP enrollee population. Individuals reporting
current tobacco use (defined as having smoked a
cigarette in the past 30 days, even a puff ) on the baseline
survey with a valid home address, and an adequate profi-
ciency in English to complete study surveys and partici-
pate in telephone counseling are randomized with equal
likelihood to receive either 1) proactive outreach com-
bined with free nicotine replacement therapy (NRT) and
telephone counseling, or 2) usual (reactive) care available
from primary care providers and/or existing telephone
helpline programs. The target recruitment goal is 2500
current cigarette smokers.
Outcome data is being collected from a follow-up sur-
vey conducted 12 months after randomization as well
as from the MHCP administrative data (e.g., pharmacy
claims data) for the twelve months following rando-
mization. Since this is a cessation-induction trial
(i.e., evaluation of an intervention to encourage cessation
among a population-based sample of smokers, including
those not currently trying to quit), it is problematic
to tie follow-up of cessation outcomes to multiple
quit dates. The Society for Research on Nicotine andTobacco (SRNT) Measures Workgroup recommends
that, for cessation-induction trials, follow-ups should be
tied to the onset of the intervention, as opposed to aid-
to-cessation trials (e.g., efficacy trials of pharmacother-
apy) which tie follow-up to the quit date [21].Usual care comparison group
All MHCP enrollees are assigned a primary care pro-
vider and usual care participants are able to see their
provider to access smoking cessation treatment. How-
ever, depending on the primary care provider’s willing-
ness and capacity to adhere to guidelines, tobacco
treatment is variable, ranging from brief advice and
medications to intensive counseling. Usual care partici-
pants also have access to smoking cessation medications
at substantially reduced cost because MHCP provides
insurance coverage for all recommended first-line nico-
tine replacement products (patch, gum, lozenge, inhaler,
and nasal spray), as well as sustained-release bupropion
and varenicline. However, an enrollee must obtain a
prescription from a provider. Enrollees who fill a pre-
scription may have a co-payment of between $1-$5.
Participants can also buy nicotine replacement products
out-of-pocket, which are available over-the-counter
(i.e., patch, gum, lozenge). Additionally, all residents of
Minnesota can access free tobacco treatment counseling
from the state quitline (1-888-354-PLAN).
In sum, participants assigned to usual care are able to
receive the same or similar smoking cessation treatment
components (including pharmacotherapy and telephone
counseling) as those given to participants in the pro-
active care intervention group. What differs is that par-
ticipants in the proactive intervention are specifically
invited – through the methods of proactive outreach –
to consider treatment for tobacco dependence, and given
facilitated access to treatment options, whereas partici-
pants in the usual care intervention must self-initiate ac-
cess to treatment.Proactive care intervention
The proactive tobacco treatment intervention is based
on social cognitive theory (SCT) [22], the stages of
change model [23] and the biopsychosocial model of
perceived discrimination [24]. Proactive care through
mailed invitation materials, outreach calls, and the offer
of free NRT along with telephone counseling is expected
to largely address provider and patient barriers to initiat-
ing care. The proactive care intervention combines two
primary components: 1) proactive outreach (a mailed
invitation letter followed by telephone outreach) and
2) facilitated access to comprehensive, evidence-based
smoking cessation treatment (free telephone counseling
and free NRT). Participants are able to choose from one
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gum, or lozenge).
Proactive outreach
All participants assigned to the proactive care interven-
tion arm are mailed personalized invitation materials.
The invitation packet includes a letter and brochure de-
scribing the types of tobacco treatment services available
to help MHCP enrollees quit smoking. To help them
access the available treatment, the materials include
instructions for enrollees interested in discussing their
smoking to (a) call a toll free number to speak directly
with a smoking cessation counselor or (b) return, in a
self-addressed stamped envelope, a reply card with con-
tact information.
Three weeks after the mailed invitation materials are
sent (or earlier for participants who respond), partici-
pants receive an outreach call from a counselor trained
in motivational interviewing and smoking cessation
treatment. Up to 6 contact attempts are made at differ-
ent times of the day (i.e., morning, afternoon, evening)
during the week. The purpose of the outreach call is to
1) deliver motivational advice to quit smoking, 2) pro-
mote self-efficacy, 3) encourage participants to partici-
pate in smoking cessation treatment, and 4) provide
information on the safety, efficacy, and functional bene-
fits of pharmacotherapy, particularly NRT. However,
both a participant’s willingness to engage in this type
of discussion and his or her receptivity to treatment-
relevant information is variable. Counselors employ mo-
tivational interviewing techniques with consideration for
the participants’ current stage of change [25]. For ex-
ample, the counselor asks, “Can we talk about your
smoking behavior to see what services might be best for
you now or in the future?” Then the counselor assesses
the participant’s readiness to quit smoking using a scale
from 0 (“no thought of quitting”) to 10 (“taking action to
quit”) [26]. The content for the call is then tailored to
the smoker’s readiness to quit, individual concerns about
quitting, and the associated SCT factors that must be
targeted to promote progression through the stages
of change, such as self-efficacy and outcome expecta-
tions. Because motivational interviewing uses a patient-
centered, autonomy-emphasizing approach, rapport may
be more easily established, especially among those not
highly motivated to quit. Our findings from focus groups
with low-income and minority smokers who had nega-
tive experiences with being “told” to quit or “scared” into
quitting support this approach [27].
Telephone care
Telephone care in this study combines free proactive
phone-based counseling with free NRT. The telephone
counseling protocol is similar to that used by statequitlines. Specifically, we use an adaptation of the
evidence-based California Helpline protocol, which
uses a combination of motivational interviewing and
cognitive-behavioral treatment for substance abuse [28].
This standard telephone counseling protocol consists of
7 calls initiated by the counselor, scheduled in a relapse-
sensitive fashion over a 2-month period (pre-quit,
quit day, then 3 days, 1 week, 2 weeks, 1 months, and
2 months after the quit date). In the pre-quit session, a
major portion of the counseling is spent promoting
smokers’ self-efficacy using motivational interviewing.
Smokers are asked to identify situations in which it
would be most difficult to refrain from smoking and to
plan realistic coping strategies. During the follow-up
calls, the emphasis is on successful implementation of
effective coping strategies and relapse prevention. Given
variability in participants’ levels of motivation and suc-
cess with quitting, counseling calls are individually
tailored to the participant’s level of motivation and pro-
gress. For example, participants who are thinking about
quitting but not ready to set a quit date right away,
receive motivational interviewing to enhance their readi-
ness to quit. In addition, participants who relapse to
smoking are encouraged to set new quit dates using
motivational interviewing and repeat the counseling
program. In total, a participant is able to receive up to
14 counseling calls.Free NRT
The study also provides a free 8-week course of NRT
(patch, gum or lozenge), which is mailed directly to par-
ticipants in anticipation of their quit date. The protocol
is based on the US Public Health Service Guideline rec-
ommendations [29,30]. All participants who receive tele-
phone counseling are offered NRT unless they have one
of the following contraindications: 1) recent (within
2 weeks) heart attack or severe arrhythmia, 2) unstable
angina, 3) pregnancy; or they decline medication. If par-
ticipants are interested in other smoking cessation medi-
cations (e.g., bupropion, varenicline), they are referred to
their primary care provider to obtain a prescription. Par-
ticipants who relapse and attempt to quit again are able
to receive an additional 4 weeks of NRT.Data collection
Data collection occurs at baseline and at 12 months
post-randomization. There are three primary sources of
individual level data for this study: 1) MHCP administra-
tive data for both pre- and post-randomization periods,
2) participant questionnaire data from baseline and
follow-up surveys, and 3) the intervention database
(intervention tracking and process data).
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Surveys, particularly of low-income populations, can be
susceptible to a low response rate [31,32]. Non-response
reduces the effective sample size and can introduce bias
and impair the validity and generalizability of results.
Mailed surveys assessing Medicaid program members’
quality of care experiences have yielded response rates
ranging from 20-50% [33]. A major advantage, however,
of using a mailed survey for MHCP enrollees is that
there is a strong incentive for enrollees to keep their ad-
dresses current in enrollment databases because many
receive supplemental income and monthly checks from
the government [31].
For the baseline tobacco use survey, we use established
modified-Dillman mailed survey procedures [34]. Up to
four mailings are sent to the selected participants over
the course of five weeks. The first mailing is a pre-
notification letter and a reply postcard to return if they
have not smoked a cigarette in the past 30 days. The
second mailing includes a $2.00 cash incentive, cover
letter, the baseline questionnaire, informed consent
information, privacy rights information and a self-
addressed, business reply envelope. Seven days later, a
reminder/thank you post card is sent to potential partici-
pants (3rd mailing). Two weeks after the postcard mail-
ing, a replacement questionnaire packet is sent to those
who have not yet responded (4th mailing).
The 12 month follow-up survey for all randomized
participants follows similar procedures as the baseline
survey except that it did not include a pre-notification
letter and additional procedures are incorporated in
order to reduce attrition. First, instead of a $2.00 incen-
tive, a larger $10.00 incentive is used with the first mail-
ing to promote retention. Second, the follow-up survey
includes phone administration (mixed-mode protocol).
Approximately five weeks after the initial mailing, partic-
ipants who did not respond to the mail protocol are
contacted for a telephone interview. At least 10 phone
call attempts are made at different times of the day and
week. Third, tracking procedures for the follow-up survey
to reduce attrition are also employed. Using a mixed-
mode approach that involves telephone interviews of
participants who do not respond to the mail protocol can
increase response rates by an additional 5 to 15% [33]. An-
other advantage of telephone interviews of mail nonre-
spondents is improved sample representativeness, which
potentially reduces nonresponse bias [35].
Outcomes
The primary outcome is self-reported six-month pro-
longed abstinence [21] at one year assessed at the
population-level (i.e., smoking abstinence among all
smokers, including those who use and those who do not
use treatment). A participant who smoked at least onceon 7 consecutive days or at least once on 2 consecutive
weekends in the six-month period is considered a treat-
ment failure. The primary outcome for both groups is
measured from the 12 month follow-up survey. Second-
ary outcomes include self-reported 7-day point preva-
lence and 30-day point prevalence, defined as having not
smoked a part of a cigarette in the past 7 days and as
having not smoked a part of a cigarette in the past
30 days, respectively. Following the Society for Research
on Nicotine & Tobacco recommendations, biochemical
verification of smoking abstinence has not been per-
formed because of the low misreporting rates in large-
scale, population based trials that have limited face-to-
face contact with study staff [36].
Additional secondary outcomes include utilization
of tobacco cessation treatment during the 12 month
follow-up (from any source, including care from outside
the study) specifically: 1) initiation of combined intensive
behavioral counseling and medication treatment, 2) initi-
ation of intensive behavioral counseling, and 3) initiation
of medication treatment. These secondary outcomes are
primarily assessed using self-report from the follow-up
survey because smokers may seek care from outside the
study due to the proactive strategies tested. Initiation of
medication treatment is defined as using one or more
tobacco dependence medications (e.g., NRT, bupropion
or varenicline) in the 12 month follow-up period. Initi-
ation of intensive counseling is defined as the comple-
tion of at least one call from a telephone counseling
program or making at least one visit to a group or indi-
vidual smoking cessation program in the 12 month
follow-up period. In addition, we will assess tobacco de-
pendence medication utilization by extracting pharmacy
claims data from the MHCP claims administrative data
and examine the prescription rates of individual medica-
tions, number of medications prescribed, and duration
of medication use.Survey measures: potential moderators and confounders
The following participant demographics are collected in
the survey: age, gender, race, ethnicity, marital status,
United States birth, size of household, number of chil-
dren in household, education, annual household income,
financial stress, and employment status.Smoking behavior
Standard questions from the California Tobacco Survey
[37], the CDC Behavioral Risk Factor Surveillance
System (BRFSS) [38] are used to collect information
regarding smoking history, such as age of smoking initi-
ation, previous quit attempts and prior use of tobacco
treatment. The Heaviness of Smoking Index is used to
assess nicotine dependence [39].
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We used instruments from the Patient Reported Out-
comes Measurement Information System (PROMIS)
developed by the NIH Roadmap initiative to assess phys-
ical functioning (short form and global health status)
[40]. To assess mental health, we used the PROMIS in-
struments for anxiety and depression (PHQ-2). To assess
alcohol use we used items from the Behavioral Risk
Factor Surveillance System (BRFSS) [38] that assess
quantity, frequency, and binge drinking. We also used




The provider factors include participants’ perceptions of
their primary care provider’s behavior related to delivery
of smoking cessation care, and perceived provider bias
and cultural competence. HEDIS tobacco performance
measures [42] assess participants’ receipt of smoking
cessation advice, counseling and treatment from their
primary care provider. We used the Physician Bias and
Interpersonal Cultural Competence Measures Scale [43]
which consists of 3 questions asking about the partici-
pant’s being treated with respect by the doctor, the doc-
tor’s understanding of the participant’s background and
values, and the participant’s feeling like the doctor looks
down on the participant’s way of life. We also assess par-
ticipant satisfaction with smoking cessation care from
their provider [44].
Cognitive factors
The cognitive factors examined in this study include
motivation to quit, self-efficacy, and attitudes toward
NRT. The Contemplation Ladder is used to assess mo-
tivation to quit and asks participants to indicate their
readiness to quit on a scale from 1 to 10 (e.g., “Think I
should quit but not quite ready”) [26]. Self-efficacy to
quit is assessed with a global measure [45]. We assess
beliefs towards NRT using the 12-item Attitudes To-
wards Nicotine Replacement Therapy (ANRT-12) scale
[46]. This scale asks participants to rate their level of
agreement or disagreement on the perceived advantages
and disadvantages of using NRT. Participants also indi-
cate their degree of certainty regarding whether or not
they intend to use NRT during their next quit attempt.
Social environment
Characteristics of the patient’s social network assessed in
the survey include: subjective norms related to smoking,
smoking habits of friends and family, and home smoking
rules [37]. We also assess day-to-day perceived discrim-
ination experienced by participants due to any cause,
not only on the basis of race, using 9 questions that askabout the frequency of exposure to day-to-day experi-
ences of discrimination such as being treated with less
courtesy, less respect, or being harassed [47]. Smoking
stigma is assessed using an adapted form of the Mental
Health Consumers’ Experience of Stigma Scale [48]. This
scale asks how frequently a participant has personally ex-
perienced sigma, like being viewed unfavorably, avoided,
or treated unfairly, because of their smoking status.
Sample size and power analysis
The power analysis assumes independent samples in the
two groups within strata and considers a type one error
rate of 0.05 for analysis of the primary outcome, six-
month prolonged abstinence. The goal sample size for
this study is N = 2500 (1250 per group), which accounts
for a 40% nonresponse rate to the follow-up survey to
ensure that we have observed smoking status outcome
data on 1500 respondents (750 per group). The antici-
pated six-month prolonged smoking abstinence rate in
the usual care arm is between 2% to 5%. This sample
size provides over 85% power to detect intervention ef-
fects if the intervention raises abstinence rates by 4%
and provides approximately 80% power or greater to de-
tect differences if the intervention raises quit rates by
3.5%. The difference this study is powered to detect is of
the same relative order of magnitude as those in prior
smoking cessation clinical trials (e.g. odds ratios of 1.5
to 2.0) [49].
Statistical analyses
The primary analysis uses intent-to-treat methodology.
The study design is a randomized complete block design
with the blocks (or strata) comprising combinations of
the two health care programs (Medicaid vs Minnesota-
Care), gender, and three age groups (18–24, 25–34, and
35–64). In the analysis we will use stratified logistic
regression methods to model the log odds of abstinence
(i.e., 6-month prolonged abstinence) or treatment utili-
zation as an additive function of intervention and the
healthcare program/age group strata. This regression
model is then used to estimate and test intervention
effects.
With our anticipated sample size, random assignment
is expected to create two groups that are balanced with
respect to observed and unobserved baseline character-
istics. However, survey nonresponse may introduce sub-
stantive imbalance between the intervention and usual
care groups. Furthermore, nonresponse may be directly
related to smoking status in a non-ignorable manner. To
investigate potential differential non-response bias, the
respondents in the two groups will be compared with
respect to baseline measures a priori known to be re-
lated to smoking cessation and treatment utilization.
Balance of the two groups will be tested using simple
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appropriate parametric tests (e.g. Blocked Anova F-tests)
or nonparametric tests (e.g. Wilcoxon rank-sum test) for
continuous variables. A common practice within the
smoking cessation research community is to treat non-
respondents at follow-up as continuing smokers. This
practice is perceived to be a conservative approach but
does not, in fact, live up to its reputation [50]. To ad-
dress potential response bias issues, we will implement a
propensity-based imputation methodology and pattern-
mixture methods in a sensitivity analysis of the primary
analyses described above.
Cost-effectiveness analysis
We will also determine the cost-effectiveness of the
intervention compared with usual care. The conduct of
the cost-effectiveness analysis will be from the adopter’s
perspective, such as the state medical assistance pro-
grams or state quitline and tobacco control programs.
From this viewpoint, costs are measured by the per par-
ticipant budgetary costs incurred as a result of imple-
menting the interventions. In practice, this cost concept
is similar to that used in many existing cost-effectiveness
analyses of smoking cessation programs. The costs to
be considered are those related to proactive outreach
(mailed invitation materials, telephone outreach), tele-
phone counseling, free NRT, data keeping, materials and
overhead. This program perspective does not include in-
direct costs incurred by individuals. The study also takes
care to distinguish those data and processing costs re-
lated to the scientific evaluation of the intervention and
those related to the intervention itself, and only include
the latter in the cost-effectiveness analysis.
The analysis uses the difference in six-month prolonged
abstinence as the effectiveness measure. Measures of
effectiveness and costs are aggregated and incremental
cost-effectiveness ratios (ICERs) will be constructed for
the two arms. The ICER takes the form: (CT – CUC)/
(OT – OUC) where (CT – CUC) is the expected difference
in the costs (C) between the treatment and usual care and
(OT –OUC) is the corresponding expected difference in
the outcome of interest (O), namely the numbers of indi-
viduals achieving prolonged abstinence at 12 months.
Such ratios can be thought of as measuring the price at
which an added unit of the outcome can be purchased by
replacing UC with the treatment. We will use bootstrap
methods to estimate standard errors and confidence inter-
vals for these cost-effectiveness measures. This approach
provides a convenient, nonparametric means of incorpor-
ating the correlation of costs and outcomes into the
resulting standard errors. Sources of uncertainty in the
specification of components of the cost measures are ad-
dressed by employing probabilistic sensitivity analyses,
where the distributions of the variables representing theanalytical assumptions are allowed to vary simultaneously,
thus testing the robustness of our findings [51]. This ana-
lysis is repeated for the different sets of sensitivity analyses
described above. In these analyses the total costs of the
intervention do not change but the effectiveness measures
changes with the different assumptions.
Discussion
There is clear evidence that low-income smokers are less
likely than higher-income smokers to use tobacco de-
pendence treatments, especially the most comprehensive
form that includes a combination of pharmacotherapy
and intensive behavioral counseling. Therefore, there is a
critical need to increase access to effective treatment
and lessen the burden of tobacco related disease among
low income populations, due to the high prevalence of
smoking. Telephone quitline services are the backbone
of universal access to tobacco dependence treatment and
are critical to the provision of smoking cessation services
to the poor and uninsured. Quitlines, however, continue
to be under-used and do not consistently provide com-
prehensive care (medications with counseling). In this
randomized controlled trial, we are testing an innovative
intervention that integrates population-based and indi-
vidual approaches to address both patient and provider
barriers to treatment that low-income smokers face. This
trial will provide evidence regarding the effects of pro-
active outreach coupled with free NRT and telephone
counseling on the population impact of tobacco depend-
ence treatment. Results of this work have the potential
to transform recommendations for promoting national
and state delivery of tobacco treatment to low-income
populations.
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